Newly-diagnosed Pediatric Ph-positive B-ALL Protocol

Prior treatment

• Treated with glucocorticoids for ≥14 days, or targeted inhibitor for \> 7 days within one month before enrollment, or any chemotherapy or any systemic anticancer therapy (including but not limited to any TKI) or radiotherapy within 3 months before enrollment (except for emergency radiotherapy to relieve airway compression).

Other illness

• Known underlying congenital immunodeficiency or metabolic disease.
• Congenital heart disease with cardiac insufficiency.
• Gastrointestinal dysfunction or gastrointestinal diseases that may significantly alter the absorption of study drug.
• Severe malnutrition, uncontrolled active infections, or serious cardiovascular diseases.
• Subjects with significant CNS disorder (e.g., uncontrolled seizure disorder, autoimmune disease involving CNS).
• Any significant comorbidities or psychiatric disorders that may impact patient safety, compliance, informed consent, study participation, follow-up, or the interpretation of study results. In such cases, all participating sites must report directly to the PI to determine whether the patient meets exclusion criteria.

Other

• Should be excluded if had any item below:
• ALL evolved from CML.

• Must meet all items below:
• Age older than 1 month to younger 18 years.
• Newly diagnosed Philadelphia chromosome-positive or BCR::ABL1-positive B-ALL.
• Written informed consent of the parents or other legally authorized guardian of the patient according to local law and regulations.